Head and Neck Cancer Trial, Recruiting NCT06472570 Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Head and Neck Cancer Trial, Recruiting

NCT06472570
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 80 years with squamous cell carcinoma or adenoid cystic carcinoma in the head and neck area who are scheduled for radical radiotherapy or combined radiation and chemotherapy (either as a primary treatment or after surgery).
  • People aged 18 to 80 years with other types of cancer in the head and neck area — such as sarcomas, neuroendocrine carcinomas, or related tumour types — who are scheduled for radical radiotherapy or combined radiation and chemotherapy (either as a primary treatment or after surgery).
  • People aged 18 to 80 years with certain non-cancerous tumours of the head and neck area (specifically tumour mixtus or paraganglioma) who require radiotherapy as a primary or post-surgical treatment.
  • People with a general health and activity level rated as reasonably functional (rated 0–2 on a standard medical scale, meaning able to carry out at least some daily activities independently).
  • People who are able to give informed, conscious agreement to take part in the trial.

Who may not be able to join:

  • People who do not meet the inclusion criteria listed above.
  • People with poorly controlled or unstable diabetes.
  • People who had a heart attack within the 6 months before the trial.
  • People who are pregnant.
  • People with a mental health condition that prevents them from being able to give conscious, informed agreement to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Paweł Polanowski, Maria Sklodowska-Curie National Research Institute of Oncology in Gliwice

Phone: 48322788313

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Registry
ClinicalTrials.gov
Start date
26 October 2019
Est. completion
31 December 2030

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

Response to treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov